Last reviewed · How we verify
NCT05532345
Discrimination of DILI and AIH by Artificial Intelligence
trial in Drug-induced Liver Injury in 2,583 participants. Completed in 31 May 2023.
31 May 2023
Quick facts
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,583 |
| Start date | 1 July 2022 |
| Primary completion | 31 May 2023 |
| Estimated completion | 31 May 2023 |
| Sites | 1 location across China |
Conditions studied
- Drug-induced Liver Injury — all drugs for Drug-induced Liver Injury →
- Autoimmune Hepatitis — all drugs for Autoimmune Hepatitis →
Sponsor
Beijing Friendship Hospital
Who can join
Eligibility, any sex, with Drug-induced Liver Injury or Autoimmune Hepatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A retrospective, multi-center, non-interventional cohort study has been going to explore whether artificial intelligence can discriminate Drug-induced liver injury and Autoimmune hepatitis. A machine learning-based tool will be developed and validated to help clinicians to differentiate between Drug-induced liver injury and Autoimmune hepatitis
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Development and Validation of a Novel Model to Discriminate Idiosyncratic Drug-Induced Liver Injury and Autoimmune Hepatitis.
Wang Y, Lin X, Sun Y, Liu J, et al · · 2025 · cited 3× · PMID 39817622 · DOI 10.1111/liv.16239 -
A Case Report: Idiopathic or Drug-Induced Autoimmune Hepatitis-Can We Draw a Line?
Božić D, Tonkić A, Vukojevic K, Radman M. · · 2023 · cited 1× · PMID 37987426 · DOI 10.3390/clinpract13060125 -
[Diagnosis and treatment of liver diseases in the era of artificial intelligence].
Ren LY, Chen DB, Chen HS. · · 2025 · PMID 41461549 · DOI 10.3760/cma.j.cn501113-20250910-00376
Verify or expand the search:
- PubMed search for NCT05532345
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Drug-induced Liver Injury
Currently open trials in the same condition.
- NCT05060289 — A Prognostic Model for Drug-induced Liver Injury in China · recruiting
Other Beijing Friendship Hospital trials
Trials by the same sponsor.
- NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
- NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
- NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
- NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05532345 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
- Last refreshed: 21 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05532345.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing